Transaction #18773 · Form 4 · 0002100154-25-000004
Century Therapeutics, Inc. · Stock award · Stock Option (right to buy)
Century Therapeutics, Inc. · Transacted December 9, 2025 · Filed December 11, 2025
What does this filing report?
An SEC Form 4 filing for Century Therapeutics, Inc. records a stock award involving Stock Option (right to buy) on December 9, 2025. The reported quantity was 88,000. The filing date is December 11, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Century Therapeutics, Inc.
- Company CIK
- 0001850119
- Security type
- Derivative
- Acquisition type
- Stock award · Code A
- Quantity acquired
- 88,000
- Reported price
- 0
- Reference value
- 0
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 88,000
- Ownership description
- Not reported
- SEC acceptance time
- Dec 11, 2025, 6:04 PM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Lee Han Myung ↗
Director
CIK 0002100154
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Derivative terms
- Underlying security
- Common Stock
- Underlying quantity
- 88,000
- Conversion / exercise price
- 0.592
- Exercise date
- Not reported
- Expiration date
- December 9, 2035
Filing footnotes & remarks
- F1
- Century Therapeutics, Inc. (the "Company") issued to the Reporting Person stock options (the "Options") in connection with his appointment as a director. The Options vest in equal monthly installments over 36 months subject to the Reporting Person's continued service to the Company and are issued pursuant to the Company's 2021 Equity Incentive Plan.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.